EURETINA 2021 Virtual Congress in review

Diabetic Eye Disease

Key to beating diabetes is better understanding for ophthalmologists

Health systems are challenged to provide appropriate care for the ever-increasing number of patients with diabetes and its complications, such as diabetic retinopathy and diabetic macular oedema.

Should NPDR patients be treated with anti-VEGF agents?

Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR)

Comparison of suitable naïve versus pretreated DMO patients

Dr Javier Zarranz-Ventura discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.

Providing optimal care for patients with diabetic eye disease

Prof Tunde Peto discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.

Gene Therapy

Optogenetic therapy for retinal degeneration shows potential of gene-independent therapeutic strategies

Dr José-Alain Sahel explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.

AMD

Brolucizumab injection improves vision in eyes with neovascular AMD

Dr Cristina Cristian noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.

AI for nAMD: Capturing more information from OCT

Dr Anat Loewenstein discussed how artificial intelligence can optimize optical coherence tomography.

Exploring the clinical and humanistic burden of geographic atrophy

During a presentation at the EURETINA 2021 Virtual Congress, Dr Daniel Jones discussed GA and emphasized the need for additional study to gain a better understanding of the burden experienced by patients.

LIGHTSITE II study: Photobiomodulation treatment improves vision in eyes with dry AMD

During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.

Cataract & Refractive

Worldwide pathological myopia discussed by panel

Dr Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.

Retinal Disease & Treatment

Addressing roadblocks of treating peripheral hemorrhagic polypoidal choroidal vasculopathy

Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Dr Chekitaan Singh discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.

Exploration of new biological treatments in posterior uveitis

Professor Quan Dong Nguyen speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.

Analysis of macula dystrophy classifications

Surgical Retina

Study investigates PCR risks associated with intravitreal injections for AMD

Dr Marta Belmonte-Grau discussed the potential risk for posterior capsular rupture during cataract surgery.

Role of anterior vitreous, managing retinal folds in retinal detachment cases

Dr Grazia Pertile discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.